Abbott Laboratories (ABT) — closed signal from July 11, 2025
Partial Published before the outcome was known, scored automatically when the window closed on October 9, 2025 — +0.2% at the close.
Predicted vs. what happened
What happened
Reached 24% of the predicted growth at its peak, without hitting the target.
The thesis — published July 11, 2025
After a small 7% slide caused by talk about new weight-loss drugs, Abbott shares sit near $132, a level that often holds. The Libre 3 Plus glucose monitor launches in Canada on 10 July and could reignite its diabetes business. Investor mood is unusually high, and similar setups have led to roughly 13% rebounds. Because the stock is about 10% cheaper than peers, a move toward $150 within three months seems realistic.
Primary drivers
- New Libre 3 Plus launch grows potential customer base, easing weight-loss drug worries.
- Oversold signal and very bullish mood have repeatedly led to quick double-digit gains.
- Shares are about 10% cheaper than similar medical-tech firms, giving price cushion.
- July-Aug earnings update could spark fresh attention and lift the share price.
How it played out
ABT: the 14% target was not reached
Lyra published ABT at $132.41 on 2025-07-11 with a short-term thesis for 14% growth toward $149.61. The thesis pointed to the Libre 3 Plus launch in Canada, worries around weight-loss drugs easing, very bullish mood, an oversold setup, a valuation about 10% cheaper than similar medical-tech firms, and a July-Aug earnings update as possible support.
Inside the window, ABT peaked at $136.88 on 2025-09-22, a 3.4% gain. It stayed below the target and never reached $149.61. The window ended at $132.72. The thesis only partially played out.
What happened during the window
On 2025-07-17, Abbott reported second-quarter sales of $11.14 billion and adjusted earnings of $1.26 per share, while narrowing its full-year adjusted earnings outlook to $5.10 to $5.20. On the same date, Investopedia reported that Abbott shares fell after the narrowed outlook, even though second-quarter revenue and adjusted earnings exceeded analyst forecasts.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.